(MDT) Medtronic - Overview
Exchange: NYSE •
Country: Ireland •
Currency: USD •
Type: Common Stock •
ISIN: IE00BTN1Y115
Stock: Pacemaker, Valve, Pump, Monitor, Stapler
Total Rating 62
Risk 86
Buy Signal -0.01
| Risk 5d forecast | |
|---|---|
| Volatility | 20.7% |
| Relative Tail Risk | -5.79% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.53 |
| Alpha | 6.68 |
| Character TTM | |
|---|---|
| Beta | 0.419 |
| Beta Downside | 0.484 |
| Drawdowns 3y | |
|---|---|
| Max DD | 22.77% |
| CAGR/Max DD | 0.38 |
EPS (Earnings per Share)
Revenue
Description: MDT Medtronic January 27, 2026
Medtronic plc (NYSE:MDT) designs, manufactures, and markets a broad range of device-based therapies across five main portfolios: Cardiovascular, Neuroscience, Medical Surgical, Diabetes, and a growing suite of digital health solutions. Its products span implantable cardiac devices, aortic and transcatheter valves, spinal and brain stimulation systems, robotic-assisted surgical tools, insulin pumps, and continuous glucose monitors, serving hospitals, physicians, and patients worldwide, with the United States accounting for roughly 60% of total sales.
Key recent metrics: FY 2023 revenue reached $31.7 billion, up 2% YoY, with the Cardiovascular segment contributing about 45% of that total; Q1 2024 reported revenue of $8.2 billion, maintaining an operating margin near 27%; R&D spending was $2.2 billion, reflecting a 9% increase year-over-year to sustain pipeline growth. The broader medical-device sector is projected to expand at a CAGR of ~6% through 2028, driven by an aging global population, rising chronic disease prevalence, and accelerating adoption of remote-monitoring technologies.
For a deeper quantitative assessment, you may find the ValueRay platform’s detailed valuation models useful.
Piotroski VR‑10 (Strict, 0-10) 9.0
| Net Income: 4.61b TTM > 0 and > 6% of Revenue |
| FCF/TA: 2.06 > 0.02 and ΔFCF/TA 200.0 > 1.0 |
| NWC/Revenue: 6.88% < 20% (prev 32.15%; Δ -25.26% < -1%) |
| CFO/TA 2.77 > 3% & CFO 7.28b > Net Income 4.61b |
| Net Debt (-4.76b) to EBITDA (9.54b): -0.50 < 3 |
| Current Ratio: 2.53 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.29b) vs 12m ago 0.16% < -2% |
| Gross Margin: 61.95% > 18% (prev 0.65%; Δ 6130 % > 0.5%) |
| Asset Turnover: 76.64% > 50% (prev 36.90%; Δ 39.74% > 0%) |
| Interest Coverage Ratio: 9.08 > 6 (EBITDA TTM 9.54b / Interest Expense TTM 712.0m) |
Altman Z'' 10.00
| A: 0.93 (Total Current Assets 4.04b - Total Current Liabilities 1.60b) / Total Assets 2.62b |
| B: 11.99 (Retained Earnings 31.48b / Total Assets 2.62b) |
| C: 0.14 (EBIT TTM 6.46b / Avg Total Assets 46.30b) |
| D: -0.00 (Book Value of Equity -181.0m / Total Liabilities 43.42b) |
| Altman-Z'' Score: 46.13 = AAA |
Beneish M -4.00
| DSRI: 0.01 (Receivables 87.0m/6.12b, Revenue 35.48b/33.20b) |
| GMI: 1.05 (GM 61.95% / 65.27%) |
| AQI: -4.65 (AQ_t -3.14 / AQ_t-1 0.68) |
| SGI: 1.07 (Revenue 35.48b / 33.20b) |
| TATA: -1.02 (NI 4.61b - CFO 7.28b) / TA 2.62b) |
| Beneish M-Score: -8.14 (Cap -4..+1) = AAA |
What is the price of MDT shares?
As of February 21, 2026, the stock is trading at USD 96.86 with a total of 7,188,694 shares traded.
Over the past week, the price has changed by -2.64%, over one month by -1.76%, over three months by -1.79% and over the past year by +13.62%.
Over the past week, the price has changed by -2.64%, over one month by -1.76%, over three months by -1.79% and over the past year by +13.62%.
Is MDT a buy, sell or hold?
Medtronic has received a consensus analysts rating of 3.81.
Therefore, it is recommended to buy MDT.
- StrongBuy: 12
- Buy: 5
- Hold: 13
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the MDT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 111.8 | 15.4% |
| Analysts Target Price | 111.8 | 15.4% |
MDT Fundamental Data Overview February 21, 2026
P/E Trailing = 26.4444
P/E Forward = 16.9492
P/S = 3.5272
P/B = 2.5713
P/EG = 2.3232
Revenue TTM = 35.48b USD
EBIT TTM = 6.46b USD
EBITDA TTM = 9.54b USD
Long Term Debt = 25.59b USD (from longTermDebt, last fiscal year)
Short Term Debt = 2.87b USD (from shortTermDebt, last fiscal year)
Debt = 28.52b USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -4.76b USD (from netDebt column, last quarter)
Enterprise Value = 148.92b USD (125.16b + Debt 28.52b - CCE 4.76b)
Interest Coverage Ratio = 9.08 (Ebit TTM 6.46b / Interest Expense TTM 712.0m)
EV/FCF = 27.53x (Enterprise Value 148.92b / FCF TTM 5.41b)
FCF Yield = 3.63% (FCF TTM 5.41b / Enterprise Value 148.92b)
FCF Margin = 15.24% (FCF TTM 5.41b / Revenue TTM 35.48b)
Net Margin = 13.00% (Net Income TTM 4.61b / Revenue TTM 35.48b)
Gross Margin = 61.95% ((Revenue TTM 35.48b - Cost of Revenue TTM 13.50b) / Revenue TTM)
Gross Margin QoQ = 64.89% (prev 60.32%)
Tobins Q-Ratio = 56.73 (set to none) (Enterprise Value 148.92b / Total Assets 2.62b)
Interest Expense / Debt = 0.63% (Interest Expense 181.0m / Debt 28.52b)
Taxrate = 18.09% (254.0m / 1.40b)
NOPAT = 5.29b (EBIT 6.46b * (1 - 18.09%))
Current Ratio = 2.53 (Total Current Assets 4.04b / Total Current Liabilities 1.60b)
Debt / Equity = 0.59 (Debt 28.52b / totalStockholderEquity, last fiscal year 48.02b)
Debt / EBITDA = -0.50 (Net Debt -4.76b / EBITDA 9.54b)
Debt / FCF = -0.88 (Net Debt -4.76b / FCF TTM 5.41b)
Total Stockholder Equity = 48.49b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.97% (Net Income 4.61b / Total Assets 2.62b)
RoE = 9.52% (Net Income TTM 4.61b / Total Stockholder Equity 48.49b)
RoCE = 8.72% (EBIT 6.46b / Capital Employed (Equity 48.49b + L.T.Debt 25.59b))
RoIC = 6.88% (NOPAT 5.29b / Invested Capital 76.88b)
WACC = 6.17% (E(125.16b)/V(153.67b) * Re(7.46%) + D(28.52b)/V(153.67b) * Rd(0.63%) * (1-Tc(0.18)))
Discount Rate = 7.46% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.05%
[DCF Debug] Terminal Value 85.38% ; FCFF base≈5.43b ; Y1≈5.52b ; Y5≈6.04b
Fair Price DCF = 132.3 (EV 164.88b - Net Debt -4.76b = Equity 169.64b / Shares 1.28b; r=6.17% [WACC]; 5y FCF grow 1.39% → 2.90% )
EPS Correlation: 20.72 | EPS CAGR: -2.92% | SUE: 2.12 | # QB: 5
Revenue Correlation: 79.82 | Revenue CAGR: 2.94% | SUE: 1.63 | # QB: 3
EPS next Quarter (2026-07-31): EPS=1.38 | Chg30d=+0.008 | Revisions Net=-1 | Analysts=22
EPS current Year (2026-04-30): EPS=5.65 | Chg30d=+0.007 | Revisions Net=-1 | Growth EPS=+2.9% | Growth Revenue=+7.8%
EPS next Year (2027-04-30): EPS=6.10 | Chg30d=-0.014 | Revisions Net=-1 | Growth EPS=+8.0% | Growth Revenue=+6.4%
P/E Forward = 16.9492
P/S = 3.5272
P/B = 2.5713
P/EG = 2.3232
Revenue TTM = 35.48b USD
EBIT TTM = 6.46b USD
EBITDA TTM = 9.54b USD
Long Term Debt = 25.59b USD (from longTermDebt, last fiscal year)
Short Term Debt = 2.87b USD (from shortTermDebt, last fiscal year)
Debt = 28.52b USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -4.76b USD (from netDebt column, last quarter)
Enterprise Value = 148.92b USD (125.16b + Debt 28.52b - CCE 4.76b)
Interest Coverage Ratio = 9.08 (Ebit TTM 6.46b / Interest Expense TTM 712.0m)
EV/FCF = 27.53x (Enterprise Value 148.92b / FCF TTM 5.41b)
FCF Yield = 3.63% (FCF TTM 5.41b / Enterprise Value 148.92b)
FCF Margin = 15.24% (FCF TTM 5.41b / Revenue TTM 35.48b)
Net Margin = 13.00% (Net Income TTM 4.61b / Revenue TTM 35.48b)
Gross Margin = 61.95% ((Revenue TTM 35.48b - Cost of Revenue TTM 13.50b) / Revenue TTM)
Gross Margin QoQ = 64.89% (prev 60.32%)
Tobins Q-Ratio = 56.73 (set to none) (Enterprise Value 148.92b / Total Assets 2.62b)
Interest Expense / Debt = 0.63% (Interest Expense 181.0m / Debt 28.52b)
Taxrate = 18.09% (254.0m / 1.40b)
NOPAT = 5.29b (EBIT 6.46b * (1 - 18.09%))
Current Ratio = 2.53 (Total Current Assets 4.04b / Total Current Liabilities 1.60b)
Debt / Equity = 0.59 (Debt 28.52b / totalStockholderEquity, last fiscal year 48.02b)
Debt / EBITDA = -0.50 (Net Debt -4.76b / EBITDA 9.54b)
Debt / FCF = -0.88 (Net Debt -4.76b / FCF TTM 5.41b)
Total Stockholder Equity = 48.49b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.97% (Net Income 4.61b / Total Assets 2.62b)
RoE = 9.52% (Net Income TTM 4.61b / Total Stockholder Equity 48.49b)
RoCE = 8.72% (EBIT 6.46b / Capital Employed (Equity 48.49b + L.T.Debt 25.59b))
RoIC = 6.88% (NOPAT 5.29b / Invested Capital 76.88b)
WACC = 6.17% (E(125.16b)/V(153.67b) * Re(7.46%) + D(28.52b)/V(153.67b) * Rd(0.63%) * (1-Tc(0.18)))
Discount Rate = 7.46% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.05%
[DCF Debug] Terminal Value 85.38% ; FCFF base≈5.43b ; Y1≈5.52b ; Y5≈6.04b
Fair Price DCF = 132.3 (EV 164.88b - Net Debt -4.76b = Equity 169.64b / Shares 1.28b; r=6.17% [WACC]; 5y FCF grow 1.39% → 2.90% )
EPS Correlation: 20.72 | EPS CAGR: -2.92% | SUE: 2.12 | # QB: 5
Revenue Correlation: 79.82 | Revenue CAGR: 2.94% | SUE: 1.63 | # QB: 3
EPS next Quarter (2026-07-31): EPS=1.38 | Chg30d=+0.008 | Revisions Net=-1 | Analysts=22
EPS current Year (2026-04-30): EPS=5.65 | Chg30d=+0.007 | Revisions Net=-1 | Growth EPS=+2.9% | Growth Revenue=+7.8%
EPS next Year (2027-04-30): EPS=6.10 | Chg30d=-0.014 | Revisions Net=-1 | Growth EPS=+8.0% | Growth Revenue=+6.4%